Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity
Idiosyncratic drug hepatotoxicity represents a major problem in drug development due to inadequacy of current preclinical screening assays, but recently established rodent models utilizing bacterial LPS co-administration to induce an inflammatory background have successfully reproduced idiosyncratic...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
Elsevier Ltd.
2011
|
| Online Access: | http://hdl.handle.net/1721.1/67046 https://orcid.org/0000-0002-3320-3969 https://orcid.org/0000-0002-1801-5548 |
| _version_ | 1826209358410678272 |
|---|---|
| author | Xu, Jinghai J. Hendriks, Bart S. Cosgrove, Benjamin D. King, Bracken Matheny Hasan, Maya A. Alexopoulos, Leonidas G. Farazi, Paraskevi A. Sorger, Peter K. Tidor, Bruce Griffith, Linda G. Lauffenburger, Douglas A. |
| author2 | Massachusetts Institute of Technology. Biotechnology Process Engineering Center |
| author_facet | Massachusetts Institute of Technology. Biotechnology Process Engineering Center Xu, Jinghai J. Hendriks, Bart S. Cosgrove, Benjamin D. King, Bracken Matheny Hasan, Maya A. Alexopoulos, Leonidas G. Farazi, Paraskevi A. Sorger, Peter K. Tidor, Bruce Griffith, Linda G. Lauffenburger, Douglas A. |
| author_sort | Xu, Jinghai J. |
| collection | MIT |
| description | Idiosyncratic drug hepatotoxicity represents a major problem in drug development due to inadequacy of current preclinical screening assays, but recently established rodent models utilizing bacterial LPS co-administration to induce an inflammatory background have successfully reproduced idiosyncratic hepatotoxicity signatures for certain drugs. However, the low-throughput nature of these models renders them problematic for employment as preclinical screening assays. Here, we present an analogous, but high-throughput, in vitro approach in which drugs are administered to a variety of cell types (primary human and rat hepatocytes and the human HepG2 cell line) across a landscape of inflammatory contexts containing LPS and cytokines TNF, IFNγ, IL-1α, and IL-6. Using this assay, we observed drug–cytokine hepatotoxicity synergies for multiple idiosyncratic hepatotoxicants (ranitidine, trovafloxacin, nefazodone, nimesulide, clarithromycin, and telithromycin) but not for their corresponding non-toxic control compounds (famotidine, levofloxacin, buspirone, and aspirin). A larger compendium of drug–cytokine mix hepatotoxicity data demonstrated that hepatotoxicity synergies were largely potentiated by TNF, IL-1α, and LPS within the context of multi-cytokine mixes. Then, we screened 90 drugs for cytokine synergy in human hepatocytes and found that a significantly larger fraction of the idiosyncratic hepatotoxicants (19%) synergized with a single cytokine mix than did the non-hepatotoxic drugs (3%). Finally, we used an information theoretic approach to ascertain especially informative subsets of cytokine treatments for most highly effective construction of regression models for drug- and cytokine mix-induced hepatotoxicities across these cell systems. Our results suggest that this drug–cytokine co-treatment approach could provide a useful preclinical tool for investigating inflammation-associated idiosyncratic drug hepatotoxicity. |
| first_indexed | 2024-09-23T14:21:17Z |
| format | Article |
| id | mit-1721.1/67046 |
| institution | Massachusetts Institute of Technology |
| language | en_US |
| last_indexed | 2024-09-23T14:21:17Z |
| publishDate | 2011 |
| publisher | Elsevier Ltd. |
| record_format | dspace |
| spelling | mit-1721.1/670462022-10-01T20:47:37Z Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity Xu, Jinghai J. Hendriks, Bart S. Cosgrove, Benjamin D. King, Bracken Matheny Hasan, Maya A. Alexopoulos, Leonidas G. Farazi, Paraskevi A. Sorger, Peter K. Tidor, Bruce Griffith, Linda G. Lauffenburger, Douglas A. Massachusetts Institute of Technology. Biotechnology Process Engineering Center Massachusetts Institute of Technology. Cell Decision Process Center Massachusetts Institute of Technology. Department of Biological Engineering Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science Lauffenburger, Douglas A. Cosgrove, Benjamin D. King, Bracken Matheny Hasan, Maya A. Alexopoulos, Leonidas G. Farazi, Paraskevi A. Sorger, Peter K. Tidor, Bruce Griffith, Linda G. Lauffenburger, Douglas A. Idiosyncratic drug hepatotoxicity represents a major problem in drug development due to inadequacy of current preclinical screening assays, but recently established rodent models utilizing bacterial LPS co-administration to induce an inflammatory background have successfully reproduced idiosyncratic hepatotoxicity signatures for certain drugs. However, the low-throughput nature of these models renders them problematic for employment as preclinical screening assays. Here, we present an analogous, but high-throughput, in vitro approach in which drugs are administered to a variety of cell types (primary human and rat hepatocytes and the human HepG2 cell line) across a landscape of inflammatory contexts containing LPS and cytokines TNF, IFNγ, IL-1α, and IL-6. Using this assay, we observed drug–cytokine hepatotoxicity synergies for multiple idiosyncratic hepatotoxicants (ranitidine, trovafloxacin, nefazodone, nimesulide, clarithromycin, and telithromycin) but not for their corresponding non-toxic control compounds (famotidine, levofloxacin, buspirone, and aspirin). A larger compendium of drug–cytokine mix hepatotoxicity data demonstrated that hepatotoxicity synergies were largely potentiated by TNF, IL-1α, and LPS within the context of multi-cytokine mixes. Then, we screened 90 drugs for cytokine synergy in human hepatocytes and found that a significantly larger fraction of the idiosyncratic hepatotoxicants (19%) synergized with a single cytokine mix than did the non-hepatotoxic drugs (3%). Finally, we used an information theoretic approach to ascertain especially informative subsets of cytokine treatments for most highly effective construction of regression models for drug- and cytokine mix-induced hepatotoxicities across these cell systems. Our results suggest that this drug–cytokine co-treatment approach could provide a useful preclinical tool for investigating inflammation-associated idiosyncratic drug hepatotoxicity. Pfizer Inc. Institute for Collaborative Biotechnologies MIT Center for Cell Decision Processes National Institute of Mental Health (U.S.) (grant P50-GM68762) National Institute of Mental Health (U.S.) (grant T32-GM008334) Massachusetts Institute of Technology. Biotechnology Process Engineering Center Massachusetts Institute of Technology. Center for Environmental Health Sciences National Institute of Mental Health (U.S.) (grant U19ES011399) Whitaker Foundation 2011-11-16T23:05:43Z 2011-11-16T23:05:43Z 2009-06 2009-03 Article http://purl.org/eprint/type/JournalArticle 0041-008X http://hdl.handle.net/1721.1/67046 Cosgrove, Benjamin D. et al. “Synergistic drug–cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity.” Toxicology and Applied Pharmacology 237 (2009): 317-330. Web. 16 Nov. 2011. © 2009 Elsevier Ltd. https://orcid.org/0000-0002-3320-3969 https://orcid.org/0000-0002-1801-5548 en_US http://dx.doi.org/10.1016/j.taap.2009.04.002 Toxicology and Applied Pharmacology Creative Commons Attribution-Noncommercial-Share Alike 3.0 http://creativecommons.org/licenses/by-nc-sa/3.0/ application/pdf Elsevier Ltd. PubMed Central |
| spellingShingle | Xu, Jinghai J. Hendriks, Bart S. Cosgrove, Benjamin D. King, Bracken Matheny Hasan, Maya A. Alexopoulos, Leonidas G. Farazi, Paraskevi A. Sorger, Peter K. Tidor, Bruce Griffith, Linda G. Lauffenburger, Douglas A. Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity |
| title | Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity |
| title_full | Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity |
| title_fullStr | Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity |
| title_full_unstemmed | Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity |
| title_short | Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity |
| title_sort | synergistic drug cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation associated idiosyncratic drug hepatotoxicity |
| url | http://hdl.handle.net/1721.1/67046 https://orcid.org/0000-0002-3320-3969 https://orcid.org/0000-0002-1801-5548 |
| work_keys_str_mv | AT xujinghaij synergisticdrugcytokineinductionofhepatocellulardeathasaninvitroapproachforthestudyofinflammationassociatedidiosyncraticdrughepatotoxicity AT hendriksbarts synergisticdrugcytokineinductionofhepatocellulardeathasaninvitroapproachforthestudyofinflammationassociatedidiosyncraticdrughepatotoxicity AT cosgrovebenjamind synergisticdrugcytokineinductionofhepatocellulardeathasaninvitroapproachforthestudyofinflammationassociatedidiosyncraticdrughepatotoxicity AT kingbrackenmatheny synergisticdrugcytokineinductionofhepatocellulardeathasaninvitroapproachforthestudyofinflammationassociatedidiosyncraticdrughepatotoxicity AT hasanmayaa synergisticdrugcytokineinductionofhepatocellulardeathasaninvitroapproachforthestudyofinflammationassociatedidiosyncraticdrughepatotoxicity AT alexopoulosleonidasg synergisticdrugcytokineinductionofhepatocellulardeathasaninvitroapproachforthestudyofinflammationassociatedidiosyncraticdrughepatotoxicity AT faraziparaskevia synergisticdrugcytokineinductionofhepatocellulardeathasaninvitroapproachforthestudyofinflammationassociatedidiosyncraticdrughepatotoxicity AT sorgerpeterk synergisticdrugcytokineinductionofhepatocellulardeathasaninvitroapproachforthestudyofinflammationassociatedidiosyncraticdrughepatotoxicity AT tidorbruce synergisticdrugcytokineinductionofhepatocellulardeathasaninvitroapproachforthestudyofinflammationassociatedidiosyncraticdrughepatotoxicity AT griffithlindag synergisticdrugcytokineinductionofhepatocellulardeathasaninvitroapproachforthestudyofinflammationassociatedidiosyncraticdrughepatotoxicity AT lauffenburgerdouglasa synergisticdrugcytokineinductionofhepatocellulardeathasaninvitroapproachforthestudyofinflammationassociatedidiosyncraticdrughepatotoxicity |